Oral vitamin D, still a viable treatment option for psoriasis

Journal of Dermatological Treatment

Volumn 24, Issue 4, 2013, Pages 261-267

  Kamangar, Faranak ^a   Koo, John ^b   Heller, Misha ^c   Lee, Eric ^d   Bhutani, Tina ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Oral vitamin D; Psoriasis; Psoriasis therapies; Vitamin D

Indexed keywords

1 ALPHA HYDROXYCOLECALCIFEROL; 1 ALPHA HYDROXYVITAMIN D3; 4 AMINOHIPPURIC ACID; ALFACALCIDOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; CREATININE; ETRETIN; INULIN; PHOSPHORUS; STEROID; UNCLASSIFIED DRUG; VITAMIN D;

4 AMINOHIPPURIC ACID CLEARANCE; BEDTIME DOSAGE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CANCER PREVENTION; CARDIOVASCULAR DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; IMMUNE RESPONSE; IMMUNOMODULATION; LONG TERM CARE; OSTEOPOROSIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; URINE LEVEL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; HUMANS; PSORIASIS; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84880240239     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.643219     Document Type: Review

References (36)

1. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78: 1193-1231.
2. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2:203-216.
3. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979; 206:1188-1190.
4. Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Endocrinology. 1983;113: 1950-1957.
5. Morimoto S, Kumahara Y. A patient with psoriasis cured by 1 alpha-hydroxyvitaminD3.Med JOsakaUniv. 1985;35:51-54.
6. Morimoto S, Yoshikawa K, Kozyka T, Kitano Y, Imanaka S, Fukuo K, et al. An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol. 1986;115:421-429.
7. Morimoto S, Yoshikawa K. Psoriasis and vitamin D3. A review of our experience. Arch Dermatol. 1989;125:231-234.
8. Smith EL, Pincus SH, Donovan L, Holick MF. A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis. J Am Acad Dermatol. 1988;19: 516-528.
9. Takamoto S, Onishi T, Morimoto S, Imanaka S, Yukawa S, Kozuka T, et al. Effect of 1 alpha-hydroxycholecalciferol on psoriasis vulgaris: A pilot study. Calcif Tissue Int. 1986;39: 360-364.
10. Ezquerra GM, Regana MS, Millet PU. Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis. Acta Derm Venereol. 2007;87:449-450.
11. Boisseau-Gersaud AM, Legrain V, Hehunstre JP, Maleville J, Taieb A. Treatment of psoriasis by oral calcitriol. A study of 5 cases and review of the literature. Ann Dermatol Venereol. 1993;120:669-674.
12. Morimoto S, Onishi T, Imanaka S, Yukawa H, Kozuka T, Kitano Y, et al. Topical administration of 1,25-dihydroxyvitamin D3 for psoriasis: Report of five cases. Calcif Tissue Int. 1986;38:119-122.
13. Morimoto S, Yoshikawa K, Kozuka T, Kitano Y, Imanaka S, Fukuo K, et al. Treatment of psoriasis vulgaris with oral 1 alpha,25-dihydroxyvitamin D3-report of two cases. J Dermatol. 1987;14:59-62.
14. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol. 1996;134: 1070-1078.
15. Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: A pilot study. Arthritis Rheum. 1990;33:1723-1727.
16. Gaál J, Lakos G, Zodoray P, Kiss J, Horváth I, Horkay E, et al. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: Results of an open, follow-up pilot study. Acta Derm Venereol. 2009;89:140-144.
17. MacLaughlin JA, Gange W, Taylor D, Smith E, Holick MF. Cultured psoriatic fibroblasts from involved and uninvolved sites have a partial but not absolute resistance to the proliferation-inhibition activity of 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA. 1985;82:5409-5412.
18. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas S.C. ,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221:1181-1183.
19. Bhalla AK, Amento EP, Serog B, Glimcher LH. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol. 1984;133:1748-1754.
20. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest. 1987;79: 1659-1664.
21. Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev. 2000;22: 203-217.
22. Smith EL, Walworth NC, Holick MF. Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol. 1986; 86:709-714.
23. Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol. 1999;112:113-116.
24. Mee JB, Cork MJ. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J Invest Dermatol. 1998;110:301-302.
25. Kontula K, Valimaki S, Kainulainen K, Viitanen AM, Keski-Oja J. Vitamin D receptor polymorphism and treatment of psoriasiswith calcipotriol. Br JDermatol. 1997;136:977-978.
26. Zhao X, Feldman D. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology. 1993; 132:1808-1814.
27. Chen ML, Perez A, Sanan DK, Heinrich G, Chen TC, Holick MF. Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol. 1996;106: 637-641.
28. Staberg B, Oxholm A, Klemp P, Christiansen C. Abnormal vitamin D metabolism in patients with psoriasis. Acta Derm Venereol. 1987;67:65-68.
29. Holick MF. Will 1,25-dihydroxyvitamin D3, MC 903, and their analogues herald a new pharmacologic era for the treatment of psoriasis? Arch Dermatol. 1989;125:1692-1697.
30. Risum G. Psoriasis exacerbated by hypoparathyroidism with hypocalcaemia. Br J Dermatol. 1973;89:309-312.
31. Stewart AF, Battaglini-Sabetta J, Millstone L. Hypocalcemiainduced pustular psoriasis of von Zumbusch. New experience with an old syndrome. Ann InternMed. 1984;100:677-680.
32. Klemp P, Staberg B. Cutaneous blood flow in psoriasis. J Invest Dermatol. 1983;81:503-506.
33. Brickman AS, Coburn JW, Friedman GR, Okamura WH, Massry SG, Norman AW. Comparison of effects of 1 alphahydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. J Clin Invest. 1976;57:1540-1547.
34. van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R, Mathieu C. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation. 2000;69:1932-1942.
35. Raisanen-Sokolowski AK, Pakkala IS, Samila SP, Binderup L, Hayry PJ, Pakkala ST. A vitamin D analog, MC1288, inhibits adventitial inflammation and suppresses intimal lesions in rat aortic allografts. Transplantation. 1997;63:936-941.
36. Koo J. Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41(3 Pt 2):S25-S28.